Semalytix, the German firm that helps doctors get AI-powered data tools to help the doctors and pharmaceutical companies has announced securing €4.3 million as part of Series A financing. VC firm btov Partners led the latest funding with participation from existing investor Fly Ventures. The round also saw participation from unnamed backers as well. Prior to this round, the firm had picked up an undisclosed seed captain in 2018 when Fly Ventures led the round along with support from other angels.
Semalytix was founded in 2015 by Janik Jaskolski, Matthias Hartung, Philipp Cimiano, and Roman Klinger. the firm has developed Pharos is an AI-based real-world evidence generation tool that ingests data and breaks it down to help the doctors and experts. The tool helps in the development of new drugs and treatments.
Janik Jaskolski, the CEO of the firm talking about the vision of the firm says that "we help make patient insights a real Northstar KPI in drug development. Due to new regulatory initiatives (and public pressure), pharma needs to demonstrate patient-centricity in drug development, [and] include the patient perspective into decision making and produce evidence that their treatments provide value in the real world.”
The company takes a unique approach to gather the data. Jaskolski commenting on the same said, “If asked, a patient will often tell a different story about how a disease impacts their life and what they need to improve it, compared to what a doctor would say. Which is why we don’t analyze physician or hospital data. Instead, we are looking at already existing public data that patients share online, in their own authentic voice, all around the world”.
The firm claims that they have insights from 25,000,000 data sources worldwide, in 11 languages for all diseases and they aim to increase the numbers significantly in the coming days.